GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Unrestricted access to all Essential and Insights content Access to the PRWeek Consultancy Tracker and the Top 150 Monthly Trading Tracker Hub In-depth reports including quarterly and annual ...

GSK has drawn on a vast bank of images and conversations from key global markets to help it establish a series of evolving “Health & Wellness Codes”. As GSK prepares to separate its pharma and ...

GSK plc announced an update regarding its total voting rights and capital for shareholders, as required by the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. As of December ...

ICICI Direct recommended hold rating on GSK Consumer with a target price of ... of Boost and Horlicks will see lower volume growth in health food drinks and earnings growth over three years ...

Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK ...

In July 2022, GSK de-merged its Consumer Healthcare segment into a standalone company. The independent Consumer Healthcare company was named Haleon HLN. GSK is witnessing increased sales growth in ...

A pat­ent dis­pute between GSK sub­si­di­ary ViiV Health­care and Colom­bian reg­u­lat­ors is not cur­rently before the Inter­na­tional Centre for Set­tle­ment of Invest­ment Dis ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

GSK CEO Emma Walmsley's bet on Arexvy has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and delayed the recommendation for ...